{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-038593","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.624236+00:00","generated_at":"2026-06-22T23:32:06.187738+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed Q3 revenue $67.7M (+45% YoY); net loss $1.09/share; secures $775M financing","bullets":["ARIKAYCE total revenue of $67.7M: $49.5M U.S., $14.5M Japan, $3.7M Europe/RoW.","Net loss of $131.1M ($1.09 per share) vs $112.7M ($0.96) in Q3 2021.","Cash and marketable securities $513.3M; strategic financings added $775M gross proceeds.","Full-year 2022 ARIKAYCE revenue expected to grow at least 30% YoY.","Phase 3 ASPEN (brensocatib) enrollment on track; topline data expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-038593","json":"https://secwatch.observer/filing/0001140361-22-038593.json","markdown":"https://secwatch.observer/filing/0001140361-22-038593.md","text":"https://secwatch.observer/filing/0001140361-22-038593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/brhc10043308_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:32:06.187738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"536e6613eb8ce6a0716d5e38913cf8c09d5d9751","claim":"INSMED Inc reported full-year 2022 results: revenue at least 30% year over year. Guidance reaffirmed.","evidence_excerpt":"Insmed continues to expect full-year 2022 global revenues for ARIKAYCE to increase at least 30% year over year from 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"Revenue","value":"at least 30% year over year"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e62923b89a5ad795c478bb284a28b045ecc5fcae","claim":"INSMED Inc reported three months ended September 30, 2022 results: net income $131.1 million, EPS $1.09.","evidence_excerpt":"Insmed reported a net loss of $131.1 million, or $1.09 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Net income","value":"$131.1 million"},{"label":"EPS","value":"$1.09"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f416caed02db2fb8d8258bf619ccc33305c37845","claim":"INSMED Inc reported three months and nine months ended September 30, 2022 results: revenue $67.7 million, net income $131.1 million, EPS $1.09. Guidance reaffirmed.","evidence_excerpt":"Total revenue for the third quarter ended September 30, 2022, was $67.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months and nine months ended September 30, 2022"},{"label":"Revenue","value":"$67.7 million"},{"label":"Net income","value":"$131.1 million"},{"label":"EPS","value":"$1.09"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}